Development of a highly sensitive, high-throughput, mass spectrometry-based assay for rat procollagen type-I N-terminal propeptide (PINP) to measure bone formation activity

Journal of Proteome Research

Volumn 6, Issue 11, 2007, Pages 4218-4229

  Han, Bomie ^a   Copeland, Marci ^b   Geiser, Andrew G ^a   Hale, Laura V ^a   Harvey, Anita ^a   Ma, Yanfei L ^b   Powers, Connie S ^a   Sato, Masahiko ^a   You, Jinsam ^b   Hale, John E ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Monarch LifeSciences   (United States)

Author keywords

Biomarker; Ion trap; Mass spectrometry; Multiple reaction monitoring (MRM); Osteoporosis; PINP; Proteomics; PTH

Indexed keywords

PREDNISOLONE; PROCOLLAGEN; PROTEIN PINP; UNCLASSIFIED DRUG;

ARTICLE; BONE DENSITY; CONTROLLED STUDY; MASS SPECTROMETRY; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOIMMUNOASSAY; RAT; SEQUENCE ANALYSIS;

ANIMALS; BIOLOGICAL MARKERS; BONE AND BONES; BONE DEVELOPMENT; CATTLE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; GOATS; GUINEA PIGS; HORSES; MASS SPECTROMETRY; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; PREDNISOLONE; PROCOLLAGEN; RABBITS; RADIOIMMUNOASSAY; RATS; RATS, SPRAGUE-DAWLEY; SENSITIVITY AND SPECIFICITY; SHEEP; SWINE;

ANIMALIA; RATTUS;

EID: 36348952115     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr070288s     Document Type: Article

References (25)

1. Cummings, S. R.; Bates, D.; Black, D. M. Clinical use of bone densitometry: scientific review. JAMA 2002, 288(15), 1889-1897.
2. Frolik, C. A.; Cain, R. L.; Sato, M.; Harvey, A. K.; Chandrasekhar, S.; Black, E. C.; Tashjian, A. H., Jr.; Hock, J. M. Comparison of recombinant human PTH(1-34) (LY333334) with a C-terminally substituted analog of human PTH-related protein(1-34) (RS-66271): In vitro activity and in vivo pharmacological effects in rats. J. Bone Miner. Res. 1999, 14(2), 163-172.
3. Neer, R. M.; Arnaud, C. D.; Zanchetta, J. R.; Prince, R.; Gaich, G. A.; Reginster, J. Y.; Hodsman, A. B.; Eriksen, E. F.; Ish-Shalom, S.; Genant, H. K.; Wang, O.; Mitlak, B. H. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 2001, 344(19), 1434-1441.
4. Kress, B. C.; Mizrahi, I. A.; Armour, K. W.; Marcus, R.; Emkey, R. D.; Santora, A. C., 2nd, Use of bone alkaline phosphatase to monitor alendronate therapy in individual postmenopausal osteoporotic women. Clin. Chem. 1999, 45(7), 1009-1017.
5. Hill, C. S.; Wolfen, R. L. The preparation of monoclonal antibodies which react preferentially with human bone alkaline phosphatase and not liver alkaline phosphatase. Clin. Chim. Acta 1990, 186(2), 315-320.
6. Rosenquist, C.; Qvist, P.; Bjarnason, N.; Christiansen, C. Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Clin. Chem. 1995, 41(10), 1439-1445.
7. Ivaska, K. K.; Hentunen, T. A.; Vaaraniemi, J.; Ylipahkala, H.; Pettersson, K.; Vaananen, H. K. Release of intact and fragmented osteocalcin molecules from bone matrix during bone resorption in vitro. J. Biol. Chem. 2004, 279(18), 18361-18369.
8. Dominguez Cabrera, C.; Sosa Henriquez, M.; Traba, M. L.; Alvarez Villafane, E.; de la Piedra, C. Biochemical markers of bone formation in the study of postmenopausal osteoporosis. Osteoporosis Int. 1998, 8(2), 147-151.
9. Chen, P.; Satterwhite, J. H.; Licata, A. A.; Lewiecki, E. M.; Sipos, A. A.; Misurski, D. M.; Wagman, R. B. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J. Bone Miner. Res. 2005, 20(6), 962-970.
10. Melkko, J.; Kauppila, S.; Niemi, S.; Risteli, L.; Haukipuro, K.; Jukkola, A.; Risteli, J. Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin. Chem. 1996, 42(6 Pt 1), 947-954.
11. Hale, J. E.; Butler, J. P.; Gelfanova, V.; You, J. S.; Knierman, M. D. A simplified procedure for the reduction and alkylation of cysteine residues in proteins prior to proteolytic digestion and mass spectral analysis. Anal. Biochem. 2004, 333(1), 174-181.
12. Hale, L. V.; Galvin, R. J.; Risteli, J.; Ma, Y. L.; Harvey, A. K.; Yang, X.; Cain, R. L.; Zeng, Q.; Frolik, C. A.; Sato, M.; Schmidt, A. L.; Geiser, A. G. PINP: a serum biomarker of bone formation in the rat. Bone 2007, 40(4), 1103-1109.
13. Hoffmann, W. E.; Everds, N.; Pignatello, M.; Solter, P. F. Automated and semiautomated analysis of rat alkaline phosphatase isoenzymes. Toxicol. Pathol. 1994, 22(6), 633-638.
14. Powers, C. S.; Schultze, A. E.; Krishnan, V.; Sato, M.; Hoffmann, W. E. Comparison of Results from the Semi-Automated Serum Bone Alkaline Phosphatase Isoenzyme Assay with the Periosteal Alkaline Phosphatase Assay for use in Rat Models. Vet. Clin. Path. in press.
15. Richter, K.; Kawashima, E.; Egger, R.; Kreil, G. Biosynthesis of thyrotropin releasing hormone in the skin of Xenopus laevis: partial sequence of the precursor deduced from cloned cDNA. EMBO J. 1984, 3(3), 617-621.
16. Schilling, S.; Niestroj, A. J.; Rahfeld, J. U.; Hoffmann, T.; Wermann, M.; Zunkel, K.; Wasternack, C.; Demuth, H. U. Identification of human glutaminyl cyclase as a metalloenzyme. Potent inhibition by imidazole derivatives and heterocyclic chelators. J. Biol. Chem. 2003, 278(50), 49773-49779.
17. Tyler-Cross, R.; Schirch, V. Effects of amino acid sequence, buffers, and ionic strength on the rate and mechanism of deamidation of asparagine residues in small peptides. J. Biol. Chem. 1991, 266(33), 22549-22556.
18. Mazziotti, G.; Angeli, A.; Bilezikian, J. P.; Canalis, E.; Giustina, A. Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol. Metab. 2006, 17(4), 144-149.
19. Pearce, G.; Tabensky, D. A.; Delmas, P. D.; Baker, H. W.; Seeman, E. Corticosteroid-induced bone loss in men. J. Clin. Endocrinol. Metab. 1998, 83(3), 801-806.
20. Awbrey, B. J.; Hagaman, J. R.; Lester, G. E.; Talmage, R. V. In vivo bone mineral analysis throughout skeletal growth in rats: differences due to sex or vitamin D deficiency. J. Orthop. Res. 1985, 3(4), 456-463.
21. Kiebzak, G. M.; Smith, R.; Howe, J. C.; Gundberg, C. M.; Sacktor, B. Bone status of senescent female rats: chemical, morphometric, and biomechanical analyses. J. Bone Miner. Res. 1988, 3(4), 439-446.
22. Sato, M.; Vahle, J.; Schmidt, A.; Westmore, M.; Smith, S.; Rowley, E.; Ma, L. Y. Abnormal bone architecture and biomechanical properties with near-lifetime treatment of rats with PTH. Endocrinology 2002, 143(9), 3230-3242.
23. Jiang, Y.; Zhao, J. J.; Mitlak, B. H.; Wang, O.; Genant, H. K.; Eriksen, E. F. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J. Bone Miner. Res. 2003, 18(11), 1932-1941.
24. Oxlund, H.; Ortoft, G.; Thomsen, J. S.; Danielsen, C. C.; Ejersted, C.; Andreassen, T. T. The anabolic effect of PTH on bone is attenuated by simultaneous glucocorticoid treatment. Bone 2006, 39(2), 244-252.
25. McClung, M. R.; San, Martin, J.; Miller, P. D.; Civitelli, R.; Bandeira, F.; Omizo, M.; Donley, D. W.; Dalsky, G. P.; Eriksen, E. F. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch. Intern. Med. 2005, 165(15), 1762-1768.